Article

Early Versus Delayed Add-on Therapy in Generalized Myasthenia Gravis: A Multicenter Real-World Cohort Study

2025-11-17

Abstract excerpt

<h4>Objective</h4> This study examined whether the timing of targeted add-on therapy initiation influences clinical outcomes in acetylcholine receptor (AChR) antibody-positive generalized myasthenia gravis (gMG), based on the hypothesis that earlier escalation may improve treatment response by intervening before structural or immunological consolidation occurs. <h4>Methods</h4> In this multicenter, retrospective...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 95e2f94c-d59d-582e-8211-0cb08c63cd5f
DOI: 10.1101/2025.11.15.25340299

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Early Versus Delayed Add-on Therapy in Generalized Myasthenia Gravis: A Multicenter Real-World Cohort StudyDOI 10.1101/2025.11.15.25340299Read

Clinical characteristics and outcome of treatment-refractory myasthenia gravis -a retrospective studySemantic proximity Read

Efgartigimod efficacy and safety in refractory Myasthenia Gravis - UK’s first real-world experienceSemantic proximity Read

Early Use of Low Dose Rituximab in Anti Acetylcholine Receptor Generalised Myasthenia Gravis in South Wales – a Retrospective StudySemantic proximity Read

A Retrospective Longitudinal Cohort Study of The Clinical Burden in Myasthenia GravisSemantic proximity Read

Real-World Case Series of Efgartigimod for Generalized Myasthenia Gravis：Well-Tailored Treatment Cycle Intervals Contribute to Sustained Symptom ControlSemantic proximity Read

Phenotype, Severity, and Therapy of Patients With LRP4 Antibody-Associated Myasthenia Gravis in the German Myasthenia Gravis Registry.Semantic proximity Read

Spotlight on MuSK Positive Myasthenia Gravis: Clinical Characteristics, Treatment and OutcomesSemantic proximity Read

Efgartigimod for Generalized Myasthenia Gravis and Beyond: A Narrative Review of its Pharmacological Profile, Clinical Utility, and Expanding ApplicationsSemantic proximity Read

Distribution and Temporal Changes of Autoantibody-Mediated Pathogenic Mechanisms Among Acetylcholine Receptor-Positive Myasthenia Gravis PatientsSemantic proximity Read

Twelve-Month Follow-Up of Patients With Generalized Myasthenia Gravis Receiving BCMA-Directed mRNA Cell TherapySemantic proximity Read

Comparison of the Efficacy and Safety of Myasthenia Gravis Treatments: A Bayesian Network Meta-AnalysisSemantic proximity Read

Prediction of myasthenia gravis generalization under immunosuppressive therapy in Northwest ChinaSemantic proximity Read